Land: USA
Sprog: engelsk
Kilde: NLM (National Library of Medicine)
MECLIZINE HYDROCHLORIDE (UNII: HDP7W44CIO) (MECLIZINE - UNII:3L5TQ84570)
Major Pharmaceuticals
MECLIZINE HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE 12.5 mg
ORAL
PRESCRIPTION DRUG
Management of nausea and vomiting, and dizziness associated with motion sickness. Meclizine HCl, USP is contraindicated in individuals who have shown a previous hypersensitivity to it.
Meclizine HCl Tablets, USP 12.5 mg, are supplied as light blue colored, oval shaped tablets with “AN 441” debossed on one side and plain on the other side. They are available as follows: 100 Tablets in unit dose blisters per box, NDC 0904-6516-61 Meclizine HCl Tablets, USP 25 mg, are supplied as light yellow colored, oval shaped tablets with “AN 442” debossed on one side and plain on the other side. They are available as follows: 100 Tablets in unit dose blisters per box, NDC 0904-6517-61 (10 cards of 10 tablets each) Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container. Rx only Distributed by: Amneal Pharmaceuticals Bridgewater, NJ 08807 Distributed By: MAJOR® PHARMACEUTICALS 17177 N Laurel Park Dr., Suite 233 Livonia, MI 48152 Rev. 10-2015-00
Abbreviated New Drug Application
MECLIZINE HYDROCHLORIDE- MECLIZINE TABLET MAJOR PHARMACEUTICALS ---------- MECLIZINE HCL TABLETS, USP DESCRIPTION Chemically, meclizine HCl, USP is 1-(_p_-chloro-α-phenylbenzyl)-4-(_m_-methylbenzyl) piperazine dihydrochloride monohydrate. Inactive ingredients for the tablets are: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium starch glycolate and talc. The 12.5 mg tablets also contain FD&C Blue #1 Aluminum Lake. The 25 mg tablets also contain D&C Yellow #10 Aluminum Lake. CLINICAL PHARMACOLOGY Meclizine HCl is an antihistamine that shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum. _PHARMACOKINETICS_ The available pharmacokinetic information for meclizine following oral administration has been summarized from published literature. _ABSORPTION_ Meclizine is absorbed after oral administration with maximum plasma concentrations reaching at a median T value of 3 hours post-dose (range: 1.5 to 6 hours) for the tablet dosage form. _DISTRIBUTION_ Drug distribution characteristics for meclizine in humans are unknown. _METABOLISM_ The metabolic fate of meclizine in humans is unknown. In an _in vitro_ metabolic study max using human hepatic microsome and recombinant CYP enzyme, CYP2D6 was found to be the dominant enzyme for metabolism of meclizine. The genetic polymorphism of CYP2D6 that results in extensive-, poor-, intermediate- and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure. _ELIMINATION_ Meclizine has a plasma elimination half-life of about 5 to 6 hours in humans. INDICATIONS AND USAGE Management of nausea and vomiting, and dizziness associated with motion sickness. CONTRAINDICA Læs hele dokumentet